Hemiplegic migraine, although a rare type of migraine its symptoms are almost same as other migraines. Intense and throbbing pain, nausea, and sensitivity to light and sound are some of the symptoms caused by hemiplegic migraine. “Hemiplegia” means paralysis and people suffering from it literally feel temporary symptoms of paralysis such as temporary weakness, numbness and tingling, and paralysis on one side of the body which start before the headache.
Although the hemiplegic migraine is considered as a rare disorder affecting a small number of people, over the past few years, the prevalence of hemiplegic migraine has been increasing. Out of the two types of hemiplegic migraine, familial hemiplegic migraine (FHM) is a hereditary condition that affects at least two close relatives in the same family.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6713
Whereas, the other type, sporadic hemiplegic migraine (SHM) can affect anyone even those who don’t have any family history of the condition. Factors such as changing lifestyle, environmental changes, pollutions, etc. are causes behind the occurrence of SHM. As a result, sporadic hemiplegic migraine is more prevalent than FHM.
However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the market growth of hemiplegic migraines.
Considering all these factors, the global hemiplegic migraine market size is expected to reach approximately 1008 MN USD by the end of 2023, growing at a CAGR of approximately 3.3% during the forecast period (2018-2023). In 2017, the market had valued at USD 830 Million.
Hemiplegic Migraine Market – Segmentations
The global hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
By treatment, the market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the market is segmented into antidepressants, botox injections, and others. By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the market is segmented into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
Hemiplegic Migraine Market - Geographical Analysis
North America accounts for the leading market for the hemiplegic migraine. Factors positively impacting the market growth in the region include the high per capita health care expenditures and rapid uptake of advanced technologies in the growing healthcare sector. Moreover, the increasing prevalence of hemiplegic migraine are fuelling the market growth in the region. Furthermore, the presence of well-established market players is positively impacting the growth in the regional market.
The Europe hemiplegic migraine market accounts for the second-largest market, globally. Attributing to the increasing healthcare expenditure, availability of advanced treatment facilities, and government initiatives, the market is estimated to register a remarkable CAGR during the forecast period (2018-2023).
The hemiplegic migraine market in the Asia Pacific region is rapidly emerging as a promising market. Growing population alongside the growing prevalence of hemiplegic migraine is driving the market in the region. Also, some of the other dominant factors such as the faster adoption of healthcare technology and government initiatives to improve the quality of healthcare are fostering the growth of the APAC market.
Hemiplegic Migraine Market - Key Players
Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co.
Innovation, mergers & acquisitions, product launch, and regional expansion remain the key trends for these players to maintain their market positions.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hemiplegic-migraine-market-6713
No comments:
Post a Comment